MedPath

Modern Biosciences Ltd.

🇬🇧United Kingdom
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.modernbiosciences.com

Clinical Trials

7

Active:1
Completed:4

Trial Phases

2 Phases

Phase 1:4
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (57.1%)
Phase 2
3 (42.9%)

Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

Phase 1
Recruiting
Conditions
Pharmacokinetics
Interventions
First Posted Date
2024-04-23
Last Posted Date
2024-08-09
Lead Sponsor
Modern Biosciences Ltd
Target Recruit Count
48
Registration Number
NCT06379958
Locations
🇬🇧

Celerion, Belfast, United Kingdom

A Study to Investigate Leramistat in Patients With IPF

Phase 2
Withdrawn
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: Placebo
First Posted Date
2023-07-19
Last Posted Date
2025-04-09
Lead Sponsor
Modern Biosciences Ltd
Target Recruit Count
150
Registration Number
NCT05951296
Locations
🇺🇸

UCSF Fresno, Fresno, California, United States

🇺🇸

National Jewish Health Main Campus, Denver, Colorado, United States

🇺🇸

MedStar Georgetown University Hospital, Washington, District of Columbia, United States

and more 53 locations

Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA

Phase 2
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo
Drug: MBS2320 5 mg
Drug: MBS2320 20 mg
Drug: MBS2320 40 mg
First Posted Date
2022-07-15
Last Posted Date
2025-04-24
Lead Sponsor
Modern Biosciences Ltd
Target Recruit Count
248
Registration Number
NCT05460832
Locations
🇧🇦

Site 1201 - Univerzitetski Klinicki Centar Republike Srpske, Banja Luka, Bosnia and Herzegovina

🇧🇦

Site 1204 - Univerzitetski Klinicki Centar Republike Srpske, Banja Luka, Bosnia and Herzegovina

🇧🇦

Site 1202 - General Hospital Gradiška, Gradiška, Bosnia and Herzegovina

and more 43 locations

Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis

Phase 2
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo
First Posted Date
2017-05-03
Last Posted Date
2019-08-14
Lead Sponsor
Modern Biosciences Ltd
Target Recruit Count
121
Registration Number
NCT03139136
Locations
🇷🇴

Arensia, Bucharest, Romania

Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis

Phase 1
Completed
Conditions
Arthritis, Rheumatoid
Interventions
First Posted Date
2015-06-25
Last Posted Date
2017-03-28
Lead Sponsor
Modern Biosciences Ltd
Target Recruit Count
105
Registration Number
NCT02480946
Locations
🇬🇧

Covance Royal Liverpool Clinical Research Unit,Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom

🇬🇧

Covance Clinical Research Unit Ltd., Leeds, West Yorkshire, United Kingdom

🇬🇧

NIHR/Wellcome Trust Imperial Clinical Research Facility (CRF), London, United Kingdom

News

No news found
© Copyright 2025. All Rights Reserved by MedPath